Real-world clinical experience with benralizumab for severe eosinophilic asthma in the Czech Republic: fewer corticosteroids and better symptom control
Clinically meaningful benefits of benralizumab treatment were confirmed in the Czech cohort, especially reduction of mOCS need, decrease of exacerbations, and improvement of asthma control.
Authors
- Beata Hutyrová
- Irena Krčmová
- Lucie Heribanová
- Norbert Pauk
- Radka Mokošová
- Martin Voříšek
- Tomáš Valena
- Mirek Maruščák
Institutions
- Charles University (CZ)
- Observatoire Français de la Sclérose en Plaques (FR)
- University Hospital Olomouc (CZ)
- AstraZeneca (Singapore) (SG)
- University Hospital Hradec Králové (CZ)
- Thomayer University Hospital (CZ)
- AstraZeneca (Germany) (DE)
- Comenius University Bratislava (SK)
Publication Details
- Journal
- Journal of Asthma
- Published
- 2025-12-27
- DOI
- https://doi.org/10.1080/02770903.2025.2610346
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00